RT Journal Article
SR Electronic
T1 Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.11.22277368
DO 10.1101/2022.07.11.22277368
A1 Kearns, Patrick K.A.
A1 Dixon, Charles
A1 Badonyi, Mihaly
A1 Lee, Kim
A1 Czapiewski, Rafal
A1 Fleming, Olivia
A1 Nadukkandy, Prajitha
A1 Gerasimivicius, Lukas
A1 Sahputra, Rinal
A1 Potts, Bethany
A1 Benton, Sam
A1 Guy, Jacky
A1 Neilson, Scott
A1 Wise, Helen
A1 Jenks, Sara
A1 Templeton, Kate
A1 ,
A1 Dold, Christina
A1 Lambe, Teresa
A1 Pollard, Andrew
A1 Mentzer, Alexander J
A1 Knight, Julian C
A1 ,
A1 Dunachie, Susanna
A1 Klenerman, Paul
A1 Barnes, Eleanor
A1 Carson, Alan
A1 McWhirter, Laura
A1 Hussell, Tracy
A1 Fragkoudis, Rennos
A1 Rosser, Susan
A1 Cavanagh, David
A1 Cowan, Graeme
A1 Menon, Madhvi
A1 Marsh, Joseph A.
A1 Kleinjan, Dirk A.
A1 Gilbert, Nick
YR 2024
UL http://medrxiv.org/content/early/2024/05/31/2022.07.11.22277368.abstract
AB Even within a single protein, antibody binding can have beneficial, neutral, or harmful effects during the response to infection. Resolving a polyclonal antibody repertoire across a pathogen’s proteome to specific epitopes may therefore explain much of the heterogeneity in susceptibility to infectious disease. However, the three-dimensional nature of antibody-epitope interactions makes the discovery of non-obvious targets challenging. We implemented a novel computational method and synthetic biology pipeline for identifying epitopes that are functionally important in the SARS-CoV-2 proteome and identified an IgM-dominant response to an exposed Membrane protein epitope which to our knowledge is the strongest correlate of severe disease identified to date (adjusted OR 72.14, 95% CI: 9.71 – 1300.15), stronger even than the exponential association of severe disease with age. We also identify persistence (> 2 years) of this IgM response in individuals with longCOVID, and a correlation with fatigue and depression symptom burden. The repetitive arrangement of this epitope and the pattern of isotype class switching is consistent with this being a previously unrecognized T independent antigen. These findings point to a coronavirus host-pathogen interaction characteristic of severe virus driven immune pathology. This epitope is a promising vaccine and therapeutic target as it is highly conserved through SARS-CoV-2 variant evolution in humans to date and in related coronaviruses (e.g. SARS-CoV), showing far less evolutionary plasticity than targets on the Spike protein. This provides a promising biomarker for longCOVID and a target to complement Spike-directed vaccination which could broaden humoral protection from severe or persistent disease or novel coronavirus spillovers.One-Sentence Summary Using a novel protein-structure-based B cell epitope discovery method with a wide range of possible applications, we have identified a simple to measure host-pathogen antibody signature associated with severe COVID-19 and longCOVID and suggest the viral Membrane protein contains an epitope that acts as a T independent antigen during infection triggering extrafollicular B cell activation.Competing Interest StatementPKAK, DJK, JAM, and NG are inventors on a preliminary application for a patent filed 9th December 2021 by University of Edinburgh titled "Thermodynamic prediction, synthesis and prioritisation of immunogenic peptides" and have no other competing interests. AC is a paid editor of JNNP, unpaid president of functional neurological disorders society and gives independent testimony in court on a range of neuropsychiatric subjects on a roughly 50% claimant 50% defender split. LMcW is unpaid as a secretary of British Neuropsychiatry Association and gives independent testimony on court on a range of neuropsychiatric subjects. TL is named as an inventor on a patent application for a vaccine against SARS CoV-2 for an unrelated project. TL was a consultant to Vaccitech for an unrelated project. AJP is chair of the UK Department of Health and Social Care's Joint Committee on Vaccination and Immunisation but does not participate in the JCVI COVID19 committee. He was previously a member of WHO's SAGE. The University of Oxford has a partnership with AstraZeneca for the development of COVID19 vaccines. Other authors declare that they have no competing interests.Funding StatementPKAK. is supported by a ECAT-Wellcome fellowship (223058/Z/21/Z) and received funding from the Chief Scientific Office and RS MacDonald Charitable Trust. NG is supported by MRC (MC_UU_00007/13). JAM is a Lister Institute Research Fellow. Lifearc, UKRI, Medical Research Scotland provided funding for development of the method. The long COVID study was funded by the chief Scientist Office Scotland. The CIRCO (Manchester) study was funded by the Wellcome Trust (202865/Z/16/Z). The Oxford cohort was funded by the UK Department of Health and Social Care as part of the PITCH (Protective Immunity from T cells to Covid-19 in Health workers) Consortium, UKRI as part of "Investigation of proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN consortium & PITCH Plus Pathway" MR/W02067X/1, with contributions from UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the Huo Family Foundation and The National Institute for Health Research (UKRIDHSC COVID-19 Rapid Response Rolling Call, Grant Reference Number COV19-RECPLAS) and the UK Vaccine Taskforce via NIHR grant to support the running of the Oxford ChAdOx1 nCoV-19 vaccine trial paid to the University of Oxford. JK was funded by UKRI (MR/W020629/1) E.B. and P.K. are NIHR Senior Investigators and P.K. is funded by WT109965MA. S.J.D. is funded by an NIHR Global Research Professorship (NIHR300791). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:North of Scotland Research Ethics Committee of the National Health Service (Scotland) gave ethical approval for the long COVID study (ref 21/NS/0035). The Research and Sample Governance Committee of the Scottish National Blood Transfusion Service gave ethical approval for the work involving blood donors (ref: SG2021/25). The Oxfordshire Research Ethics Committee C of National Health Services Health Research Authority gave ethical approval for the work involving subjects with severe COVID-19 (Oxford REC C, reference:19/SC/0296 and Oxford REC C, reference 13/SC/0149). The Northwest-Preston Research Ethics Committee of National Health Services Health Research Authority gave ethical approval for this work (Northwest-Preston REC, reference 20/NW/0235). The Sheffield Research Ethics Committee of National Health Services Health Research Authority gave ethical approval for the work recruiting recovered HCWs under the Gastrointestinal illness in Oxford: COVID sub study (ref: 16/YH/0247). The London-Brent Research Ethics Committee of the National Health Service (Scotland) gave ethical approval for this work. (NHS Lothian BioResource (SR1407) and ref: (ref: 20/HRA/3764 IRAS:28653)). The North West Haydock Research Ethics Committee of National Health Services Health Research Authority gave ethical approval for the work (ref: 15/NW/0409 for ManARTS). The Wales Research Ethics Committee 4 of Northern Care Alliance NHS Foundation Trust gave ethical approval for this work (ref: 18/WA/0368). The Edinburgh Medical School Research Ethics Committee of the University of Edinburgh gave ethical approval for this work (ref: 21/EMREC/010). All participants gave written and informed consent for serial blood sample collection.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data necessary are available in the text or the supplementary materials. Code to reproduce the analyses in the paper can be accessed from the first author's GitHub project repository. https://github.com/PKKearns/SARS2_Antibody_Profiling_Paper